Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
As of today (2026-07-14), the Forward Annual Dividend Yield of BioGend Therapeutics Co is 0.00%.
As of today (2026-07-14), the Trailing Annual Dividend Yield of BioGend Therapeutics Co is 0.00%.
ROCO:6733's Forward Dividend Yield % is not ranked *
in the Biotechnology industry.
Industry Median: 1.26 * Ranked among companies with meaningful Forward Dividend Yield % only.
The growth rate is calculated with least square regression.
For more information regarding to dividend, please check our Dividend Page.
BioGend Therapeutics Co (ROCO:6733) Forward Dividend Yield % Explanation
Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.
Dividends may also qualify a lower tax rate for investors.
In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.
BioGend Therapeutics Co Forward Dividend Yield % Related Terms
ROCO:6733 vs VRTX, REGN, ALNY: Forward Dividend Yield % Comparison
For the Biotechnology subindustry, BioGend Therapeutics Co's Forward Dividend Yield %, along with its competitors' market caps and Forward Dividend Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BioGend Therapeutics Co Forward Dividend Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, BioGend Therapeutics Co's Forward Dividend Yield % distribution charts can be found below:
* The bar in red indicates where BioGend Therapeutics Co's Forward Dividend Yield % falls into.
What does a Forward Dividend Yield % of 0.00% mean?
BioGend Therapeutics Co (ROCO:6733) has a Forward Dividend Yield % of 0.00% as of Jul. 14, 2026. Forward dividend yield is the ratio of company's expected dividends to the share price. View historical data on BioGend Therapeutics Co and its competitors. According to the industry distribution chart, BioGend Therapeutics Co ranks #999999 out of 148 companies in the Biotechnology industry.
Is BioGend Therapeutics Co's Forward Dividend Yield % too high?
BioGend Therapeutics Co's current Forward Dividend Yield % is 0.00%. Based on the distribution chart, BioGend Therapeutics Co ranks #999999 out of 148 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, BioGend Therapeutics Co has a GF Score™ of 73/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does BioGend Therapeutics Co's Forward Dividend Yield % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, BioGend Therapeutics Co ranks #999999 out of 148 companies for Forward Dividend Yield %. This places BioGend Therapeutics Co in the lower half of its industry. The industry median Forward Dividend Yield % is 1.26. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Forward Dividend Yield % for a Biotechnology company?
The median Forward Dividend Yield % among Biotechnology companies is 1.26, based on 148 companies in the industry. Companies in the top quartile (top 25%) have a Forward Dividend Yield % significantly above this median, while those in the bottom quartile fall well below. However, Forward Dividend Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Forward Dividend Yield % mean?
A high Forward Dividend Yield % can signal that a stock is expensive relative to its fundamentals. Forward dividend yield is the ratio of company's expected dividends to the share price. View historical data on BioGend Therapeutics Co and its competitors. For the Biotechnology industry, the median Forward Dividend Yield % is 1.26 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BioGend Therapeutics Co's current Forward Dividend Yield % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioGend Therapeutics Co stock overvalued right now?
Based on GuruFocus' analysis, BioGend Therapeutics Co (ROCO:6733) is currently considered Significantly Undervalued. The stock's GF Value™ is NT$70.22, compared to a current price of NT$25.35 — trading 63.9% below its estimated fair value. The current Forward Dividend Yield % is 0.00%. BioGend Therapeutics Co's overall GF Score™ is 73/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Forward Dividend Yield % calculated?
Forward Dividend Yield % is calculated from a company's financial statements. For BioGend Therapeutics Co (ROCO:6733), the current Forward Dividend Yield % is 0.00% as of Jul. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BioGend Therapeutics Co (ROCO:6733) Overvalued in 2026?
Based on GuruFocus' analysis, BioGend Therapeutics Co stock appears to be undervalued.
The current stock price of NT$25.35 is trading 63.9% below its estimated GF Value™ of NT$70.22.
GuruFocus considers BioGend Therapeutics Co to be Significantly Undervalued.
Key valuation signals for ROCO:6733:
Forward Dividend Yield %: 0.00%
GF Value™: NT$70.22 vs. price of NT$25.35 (63.9% below fair value)
No single metric tells the full story. See the ROCO:6733 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
BioGend Therapeutics Co Ltd is a Taiwan-based company involved in the research and development of orthopedic medical equipment and related products, and the sale of related products. It is involved in the research and development of inventive cartilage repair technology and products, adipose stem cell extraction technology, and others. Geographically, the company generates a majority of its revenue from Taiwan, followed by China, Malaysia, and other regions.
73GF Score
Get the complete analysis for ROCO:6733
Forward Dividend Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:6733 has been successfully added to your 
